GlassScriptPhysician profile
Matthew C Lawrence
NPI 1255324109
$5,864.53
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $375 · 2021: $1,148 · 2022: $1,560 · 2023: $1,420 · 2024: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,257.54 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,001.73 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $507.97 | 2019-2024 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $432.34 | 2019-2024 | Shingrix, Bexsero, Arexvy |
| Sanofi Pasteur INC. | $271.72 | 2021-2024 | |
| Pfizer INC. | $235.65 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $231.28 | 2019-2023 | Vaxneuvance, Gardasil 9, M-M-R II |
| Novo Nordisk INC | $203.36 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $202.06 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $172.35 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $148.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.84 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $122.08 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.42 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $121.38 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.